GSK buys cancer drugmaker Nuvalent for $10.6 billion

Overview

Updated Jun 9

GSK agreed to pay $10.6 billion in cash for Nuvalent, a Cambridge, Massachusetts biotech with two lung cancer drugs awaiting U.S. approval. At $124 a share, the price is about 40% above where Nuvalent traded before the deal. It is GSK's biggest acquisition in more than a decade.

GSK's top-selling HIV medicine starts losing patent protection in 2028. That drug brought in $5.65 billion last year. The Nuvalent deal is how GSK plans to replace some of that lost revenue with cancer drugs that could reach the market within months.

Why it matters

Two next-generation lung cancer drugs could reach patients within months, if the FDA clears them and GSK's $10.6 billion bet pays off.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

$10.6B

Deal value

All-cash purchase, GSK's largest acquisition in over a decade.

$124/share

Offer price

About a 40% premium over Nuvalent's prior share price.

40%

Premium paid

Nuvalent shares jumped roughly 39% on the news.

$5.65B

HIV revenue at risk

2025 sales of GSK's dolutegravir drugs, which lose patent protection from 2027.

Late-stage drugs

Zidesamtinib and neladalkib, both under FDA review for lung cancer.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

People Involved

Luke Miels

Chief Executive Officer, GSK

Leading GSK's push back into oncology

James Porter

Chief Executive Officer, Nuvalent

Selling Nuvalent to GSK

Organizations Involved

GSK (GlaxoSmithKline)

Pharmaceutical company

Acquirer

British drugmaker buying Nuvalent to rebuild its cancer portfolio ahead of a 2028 HIV patent cliff.

Nuvalent

Biotechnology company

Acquisition target

Cambridge, Massachusetts biotech whose two lung cancer drugs are the prize in GSK's $10.6 billion deal.

U.S. Food and Drug Administration

Federal regulatory agency

Reviewing both drugs

The U.S. regulator whose approval decisions in late 2026 will determine whether GSK's two new drugs can be sold.

Timeline

March 2015 November 2026

5 events Latest: June 9th, 2026 · 3 months ago

Tap a bar to jump to that date

November 2026
FDA ruling due on neladalkib
Upcoming Regulatory

The FDA's target decision date for Nuvalent's ALK inhibitor, the second drug central to GSK's bet.
November 27th, 2026
September 2026
FDA ruling due on zidesamtinib
Upcoming Regulatory

The FDA's target decision date for Nuvalent's ROS1 inhibitor, the first of the two drugs to face a verdict.
In 6 days
June 2026
GSK agrees to buy Nuvalent for $10.6 billion
Latest Deal

GSK offers $124 a share in cash, about a 40% premium. Nuvalent shares jump roughly 39%. It is GSK's largest acquisition in more than a decade.
June 9th, 2026
January 2021
Nuvalent launches
Corporate

Nuvalent starts with $50 million from Deerfield Management to build kinase inhibitors that overcome cancer drug resistance.
January 27th, 2021
March 2015
GSK exits most of oncology
Corporate

GSK sells the bulk of its cancer business to Novartis in an asset swap, leaving a gap it would later spend years filling.
March 2nd, 2015

Scenarios

FDA approves both Nuvalent lung cancer drugs by year-end

Likely Resolves by End of 2026

Discussed by: GSK, Fierce Biotech, UBS analysts

Both drugs hold Breakthrough Therapy status and have firm FDA decision dates in September and November. If the agency clears both, GSK can start selling them this year and begin earning back its outlay. UBS analysts expect zidesamtinib alone to reach nearly $2 billion in peak annual sales.

GSK completes the Nuvalent takeover by end of Q3

Likely Resolves by Q3 2026

Discussed by: GSK, SEC tender offer filings

GSK is buying Nuvalent through a cash tender offer it expects to fund within 10 business days of acceptance, subject to regulatory clearance and enough shares being tendered. An all-cash deal at a 40% premium gives shareholders little reason to hold out. The main variable is how fast antitrust review clears.

FDA delays or rejects at least one Nuvalent drug

Unlikely Resolves by End of 2026

Discussed by: Industry analysts tracking FDA review risk

Even drugs with strong trial data can hit a complete response letter, the FDA's term for a refusal to approve as filed. A delay or rejection on either drug would push back sales and dent the math behind GSK's $10.6 billion price. This is the main downside investors are watching.

A rival bidder tops GSK's offer for Nuvalent

Unlikely Resolves by Aug 31, 2026

Discussed by: Deal arbitrage analysts

Targeted lung cancer is a contested field where Roche and Pfizer already compete. A large drugmaker hunting for late-stage assets could counter GSK's bid, though the 40% premium and tender-offer structure make a topping bid hard. No rival offer has surfaced so far.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

November 2011

Pfizer's Lipitor patent cliff (2011)

Pfizer's cholesterol drug Lipitor, then the best-selling medicine ever at over $9 billion a year, lost U.S. patent protection. Generic copies flooded in within weeks. Pfizer's revenue dropped sharply and it spent years restructuring and buying replacements.

Then

Lipitor sales collapsed as cheaper generics took the market almost immediately.

Now

The episode became the textbook case of a patent cliff and pushed drugmakers to plan replacements years ahead.

Why this matters now

GSK faces its own cliff in 2028 as its $5.65 billion HIV franchise loses protection. The Nuvalent deal is GSK trying to line up replacement revenue before that drop hits.

December 2018

GSK buys Tesaro (2018)

GSK paid $5.1 billion for Tesaro, a Massachusetts cancer biotech, to re-enter oncology three years after selling most of that business to Novartis. The deal centered on Zejula, an ovarian cancer drug. Investors initially questioned the price.

Then

GSK shares fell on the announcement as analysts called the price steep for a single lead drug.

Now

The deal anchored GSK's return to cancer drugs and set the template for buying late-stage assets rather than building from scratch.

Why this matters now

Nuvalent is the same playbook at twice the scale: buy a Massachusetts oncology biotech with near-market drugs to rebuild a portfolio GSK once walked away from.

January 2019

Eli Lilly buys Loxo Oncology (2019)

Eli Lilly paid $8 billion for Loxo Oncology, a biotech making precision drugs that target specific cancer-causing mutations rather than tumor location. The price was a 68% premium. Loxo's drugs worked across cancer types defined by genetics.

Then

The deal gave Lilly an instant precision-oncology franchise and a marketed drug, larotrectinib.

Now

It validated paying large premiums for mutation-targeted cancer biotechs, a category Nuvalent also occupies.

Why this matters now

Like Loxo, Nuvalent designs drugs aimed at precise genetic targets. Big drugmakers keep paying steep premiums for that approach, which is exactly what GSK just did.